Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Neoplasms 3Lung Neoplasms 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available 1Non-Small Cell Lung Cancer Metastatic 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Deafness, Autosomal Recessive 39 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × tepotinib × Clear all
NCT02864992 2026-04-13

VISION

EMD Serono

Phase 2 Active not recruiting
337 enrolled 13 charts 2 FDA
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT04647838 2020-12-02

Tepotinib in Solid Tumors Harboring MET Alterations

Chungbuk National University Hospital

Phase 2 Unknown
100 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡